* Cyclo Therapeutics Inc CYTH.OQ reported a quarterly
adjusted
loss of 27 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -29 cents. The mean expectation of
three analysts for the quarter was for a loss of 16 cents per
share. Wall Street expected results to range from -19 cents
to -13 cents per share.
* Revenue fell 53% to $233.00 thousand from a year ago;
analysts
expected $294.00 thousand.
* Cyclo Therapeutics Inc's reported EPS for the quarter was
a loss
of 31 cents.
* The company reported a quarterly loss of $8.83 million.
* Cyclo Therapeutics Inc shares had fallen by 8.7% this
quarter and lost 54.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 5% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"
Wall Street's median 12-month price target for Cyclo
Therapeutics Inc is $0.95
This summary was machine generated from LSEG data November 14 at
08:55 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.16 -0.27 Missed
Jun. 30 2024 -0.15 -0.21 Missed
Mar. 31 2024 -0.20 -0.15 Beat
-0.34